Advertisement

Neuroscience and Behavioral Physiology

, Volume 44, Issue 3, pp 315–319 | Cite as

Valdoxan (agomelatine) in the Treatment of Depression in Cerebrovascular Diseases (results of the Russian Resonance multicenter naturalistic study)

  • N. V. Pizova
Article

The therapeutic efficacy and tolerance of Valdoxan (agomelatine) in the treatment of mild and moderate depression in cerebrovascular diseases (CVD) in routine neurological practice were evaluated. A total of eight Russian centers took part in the study. The study included 88 patients with CVD (18 men, 70 women) aged 40–65 (mean 55.4 ± 6.5) years. Treatment for six weeks eliminated depressive symptomatology in 81.20% of patients. Patients showed regression of fatigue, improvements in working efficiency, achievement of normal values for the coefficient of mental stability, and improvements in sleep.

Keywords

depression cerebrovascular diseases Valdoxan agomelatine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. M. Armstrong, O. M. McNulty, B. Guardiola-Lemaitre, et al., “Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS),” Pharmacol. Biochem. Behav., 46, 45–49 (1993).PubMedCrossRefGoogle Scholar
  2. 2.
    D. B. Boivin, “Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders,” J. Psychiatry Neurosci., 25, 446–458 (2000).PubMedCentralPubMedGoogle Scholar
  3. 3.
    V. Camus, H. Kraehenbuhl, M. Preisig, et al., “Geriatric depression and vascular diseases: what are the links?” J. Affect. Disord., 81, No. 1, 1–16 (2004).PubMedCrossRefGoogle Scholar
  4. 4.
    C. S. Chen, C. C. Chen,Y. T. Kuo, et al., “Carotid intima-media thickness in late-onset major depressive disorder,” Int. J. Geriatr. Psychiatry, 21, No. 1, 36–42 (2006).PubMedCrossRefGoogle Scholar
  5. 5.
    D. E. Ford and D. B. Kamerow, “Epidemiological study of sleep disturbances and psychiatric disorders: an opportunity for prevention?” J. Am. Med. Assoc., 262, 1479–1484 (1989).CrossRefGoogle Scholar
  6. 6.
    C. Holley, S. A. Murrell, and B. T. Mast, “Psychosocial and vascular risk factors for depression in the elderly,” Am. J. Geriatr. Psychiatry, 14, No. 1, 84–90 (2006).PubMedCrossRefGoogle Scholar
  7. 7.
    H. W. Konigsberg, M. H. Teicher, V. Mitropoulou, et al., “24-h monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone, and prolactin in depression,” J. Psychiatr. Res., 38, 503–511 (2004).CrossRefGoogle Scholar
  8. 8.
    K. Krauchi, C. Cajochen, D. Mori, et al., “Early evening melatonin and S-20089 advance circadian phase and nocturnal regulation of core body temperature,” Am. J. Physiol., 272, 1178–1188 (1997).Google Scholar
  9. 9.
    R. Leproult, A. Van, Onderbergen, M. L’hermite-Baleriaux, et al., “Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men,” Clin. Endocrinol. (Oxf.), 63, 298–304 (2005).CrossRefGoogle Scholar
  10. 10.
    H. Loo, A. Hale, and H. D’Haenen, “Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study,” Int. Clin. Psychopharmacol., 17, 239–247 (2002).PubMedCrossRefGoogle Scholar
  11. 11.
    L. Lustberg and C. F. Reynolds, “Depression and insomnia: questions of cause and effect,” Sleep Med. Res., 4, 253–262 (2000).CrossRefGoogle Scholar
  12. 12.
    A. G. Mayers and D. S. Baldwin, “Antidepressants and their effect on sleep,” Hum. Psychopharmacol., 20, 533–559 (2005).PubMedCrossRefGoogle Scholar
  13. 13.
    M. J. Millan, F. Lejeune, and A. Gobert, “Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents,” J. Psychopharmacol., 14, 114–138 (2000).PubMedCrossRefGoogle Scholar
  14. 14.
    M. J. Millan, A. Gobert, F. Lejeune, et al., “The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways,” J. Pharmacol. Exp. Ther., 306, 954–964 (2003).PubMedCrossRefGoogle Scholar
  15. 15.
    J. Mouret, P. Lemoine, P. Minuit, et al., “Effects of trazodone on the sleep of depressed subjects: a polygraphic study,” Psychopharmacology (Berlin), 95, 37–43 (1988).CrossRefGoogle Scholar
  16. 16.
    M. M. Ohayon and T. Roth, “Place of chronic insomnia in the course of depressive and anxiety disorders,” J. Psychiatr. Res., 37, 9–15 (2003).PubMedCrossRefGoogle Scholar
  17. 17.
    G. Rajkowska, J. J. Miguel-Hidalgo, P. Dubey, et al., “Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients,” Biol. Psychiatry, 58, No. 4, 297–306 (2005).PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    C. F. Reynolds, 3rd, “Sleep and affective disorders: a minireview,” Psychiatr. Clin. North Am., 10, 583–591 (1987).PubMedGoogle Scholar
  19. 19.
    R. P. Rosenberg, “Sleep maintenance insomnia: strengths and weakness of current pharmacologic therapies,” Ann. Clin. Psychiatry, 18, 49–56 (2006).PubMedCrossRefGoogle Scholar
  20. 20.
    T. Seki, S. Awata, Y. Koizumi, et al., “Association between depressive symptoms and cerebrovascular lesions on MRI in community-dwelling elderly individuals,” Nippon Ronen Igakkai Zasshi, 43, No. 1, 102–107 (2006).PubMedCrossRefGoogle Scholar
  21. 21.
    V. I. Spoormaker and J. van den Bout, “Depression and anxiety complaints: relations with sleep disturbances,” Eur. Psychiatry, 20, 243–245, (2005).PubMedCrossRefGoogle Scholar
  22. 22.
    L. Staner, F. Cornette, D. Maurice, et al., “Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia,” J. Sleep Res., 12, 319–331 (2003).PubMedCrossRefGoogle Scholar
  23. 23.
    O. van Reeth, L. Weibel, E. Olivares, et al., “Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus,” Am. J. Physiol. Regul. Integr. Comp. Physiol., 280, 1582–1591 (2001).Google Scholar
  24. 24.
    S. Wilson and S. Argyropoulos, “Antidepressants and sleep: a qualitative review of the literature,” Drugs, 65, 927–947 (2005).PubMedCrossRefGoogle Scholar
  25. 25.
    A. Winokur, K. A. Gary, S. Rodner, et al., “Depression, sleep physiology, and antidepressant drugs,” Depress. Anxiety, 14, 19–28 (2001).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Nervous DiseasesYaroslavl State Medical AcademyYaroslavlRussia

Personalised recommendations